SCYNEXIS to Present Data from Lead Antifungal Drug Candidate SCY-078 at 13th ASM Conference on Candida and Candidiasis

Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) announced today that results of three nonclinical studies of the company’s lead clinical drug candidate, SCY-078, will be presented in poster presentations at the 13^th American Society for Microbiology (ASM) Conference on Candida and Candidiasis that will take place from April 13 through April 17, 2016, in Seattle, WA.
According to Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS:

With antifungal resistance on the rise, there is an urgent and growing need for novel anti-fungal therapies that overcome the limitations of existing treatment classes such as azoles and echinocandins. We believe that this data demonstrates the potential of SCY-078, the first representative of a new class of glucan synthase inhibitors, in treating invasive and life-threatening fungal infections in humans and provide a strong basis for continued development of SCY-078 as a promising treatment in both first-line and refractory infections.

Click here to view the full press release.